111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, has announced that it has entered into a strategic cooperation agreement with BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide.

BeiGene currently markets two internally discovered oncology medicines in China: BTK inhibitor, BRUKINSA^® (zanubrutinib), and anti-PD-1 antibody, tislelizumab. It also markets or plans to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.

To make cancer care more efficient and patient-friendly in China, the two companies will cooperate around a "Internet + Medicine & Healthcare" model, leveraging 111's Internet hospital, smart supply chain network, data-driven AI solutions, such as digital advertising, and online and offline direct-to-patient (DTP) delivery of medicines to create an unique oncology management platform.

The platform will further empower doctors to improve the efficiency of patient management, especially for patients outside of the hospital, and will not only extend their service cycles, but also expand their service radius.

At the same time, through this efficient and convenient doctor-patient communication platform, it will be possible to provide patients with a digital, one-stop service for medical care and medicine, improving the accessibility of BeiGene's innovative oncology drugs.